Morgan Stanley’s Dimension Therapeutics, Inc DMTX Stock Holding History

Morgan Stanley’s Portfolio DMTX Stock Details DMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-19,072	Closed	-$115K	–	6908
2017 Q3	$115K	Sell	19,072 -80	-0.4%	-$207	﹤0.01%	5537
2017 Q2	$28K	Buy	19,152 +2,964	+18%	+$4.03K	﹤0.01%	6016
2017 Q1	$28K	Sell	16,188 -19,393	-55%	-$51.4K	﹤0.01%	5990
2016 Q4	$155K	Buy	35,581 +33,348	+1,493%	+$177K	﹤0.01%	5434
2016 Q3	$18K	Sell	2,233 -3,930	-64%	-$28.4K	﹤0.01%	5951
2016 Q2	$37K	Buy	6,163 +5,984	+3,343%	+$45.6K	﹤0.01%	5637
2016 Q1	$1K	Sell	179 -1,674	-90%	-$13.2K	﹤0.01%	6533
2015 Q4	$21K	Buy	+1,853	New	+$23.5K	﹤0.01%	6028

Morgan Stanley's DMTX Position: Q4 2017 in Review

Morgan Stanley sold out of Dimension Therapeutics, Inc (DMTX) in Q4 2017, closing a stake of 19,072 shares — an estimated $115K sold.

Morgan Stanley first reported a position in DMTX in Q4 2015 and held it in 8 quarters. The position peaked at $155K in Q4 2016. 0 funds tracked by Wall St. Rank hold DMTX as of Q4 2017.

Morgan Stanley reported no remaining Dimension Therapeutics, Inc position as of Q4 2017 after selling out during the quarter.
Morgan Stanley sold 19,072 Dimension Therapeutics, Inc shares in Q4 2017, an estimated $115K.
Morgan Stanley first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 8 quarters.
Morgan Stanley's Dimension Therapeutics, Inc position peaked at $155K in Q4 2016.
0 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q4 2017.

Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.